Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of UX-DA003 Injection in Parkinson's disease
CTR20262508Phase 2Active
- Sponsor
- Shanghai Yuesai Biotechnology
- Start
- Sep 2026
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of UX-DA003 in Parkinson's disease (PD), sponsored by Shanghai Yuesai Biotechnology. Started Sep 2026; status: active.
02
Drugs
UX-DA003
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20262508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262508.